Aequus Pharmaceuticals (TSE:AQS) has released an update. Aequus Pharmaceuticals reports a 77.50% increase in revenue for Q3 2024 compared to the previous year, driven by the continued growth of their
Aequus Pharmaceuticals (TSE:AQS) has released an update. Aequus Pharmaceuticals reports a 77.50% increase in revenue for Q3 2024 compared to the previous year, driven by the continued growth of their
Aequus Pharmaceuticals (TSE:AQS) has released an update. Aequus Pharmaceuticals Inc. has seen a positive second quarter in 2024 with a notable increase in revenue and a reduction in net losses
Aequus Pharmaceuticals (TSE:AQS) has released an update. Aequus Pharmaceuticals Inc. reports a record-breaking sales quarter for Zimed® PF, the first preservative-free prostaglandin analog for glaucoma in Canada, signaling strong clinician
Aequus Pharmaceuticals (TSE:AQS) has released an update. Aequus Pharmaceuticals has secured an exclusive deal with Advanced Ophthalmic Innovations to distribute the PAUL® glaucoma drainage device in Canada, a product already
Aequus Pharmaceuticals (TSE:AQS) has released an update. Aequus Pharmaceuticals Inc. reports a reduced operating loss and a decline in overall revenue in Q1 2024, largely due to halting Evolve product